Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home

Safety and tolerability of a novel chrom

Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura

✍ James B. Bussel; Kim Hanna 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract Intravenous immunoglobulin (IGIV) therapy is generally considered to be a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP). The usual initial treatment dose is 1–2 g/kg body weight, which results in an extended infusion time, significantly impacting patients' d